Tag Archives: U.S.

Sen. Sanders, Rep. Cummings to introduce bill to lower U.S. drug prices

WASHINGTON (Reuters) – U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. FILE PHOTO: A pharmacy employee looks for medication as she works to fill a prescription while working at a pharmacy in New York December 23, 2009. REUTERS/Lucas… Read More »

Medicare, Medicaid underpaid U.S. hospitals by $76.8 billion in 2017, American Hospital Association says

According to new data released by the American Hospital Association, Medicare and Medicaid underpaid U.S. hospitals by $ 76.8 billion in 2017. Medicare underpayments totaled $ 53.9 billion and Medicaid underpayments $ 22.9 billion for 2017. Meanwhile, in 2017, hospitals provided $ 38.4 billion in uncompensated care, the AHA said. THE IMPACT This means hospitals… Read More »

J&J unit to pay $360 million to U.S. to resolve charity kickback probe

BOSTON (Reuters) – A unit of Johnson & Johnson will pay $ 360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday. FILE PHOTO: The Johnson and Johnson logo is seen at an office building in Singapore… Read More »

CanGaroo Envelope Now Cleared in U.S. to Protect Implantable Neurostimulators

Aziyo Biologics, out of Silver Springs, Maryland, won FDA clearance for its CanGaroo Envelope to be used with implantable neurostimulators. It has previously been cleared only for encapsulating implantable cardiac devices such as pacemakers and defibrillators. The CanGaroo Envelope is, contrary to what its name may imply, is a porcine extracellular matrix, essentially pig’s tissue with… Read More »

AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023

AbbVie is on a hot streak striking patent deals to protect its top drug, Humira. Even as Boehringer Ingelheim has opted to fight the company’s patent claims in court, Pfizer has decided it’s in its own best interest to settle on a late 2023 biosimilar launch date. Under a licensing agreement with AbbVie, Pfizer can… Read More »